DDInter825 DDInter808
First introduced in 1995, glimepiride is a member of the second-generation sulfonylurea (SU) drug class used for the management of type 2 diabetes mellitus (T2DM) to improve glycemic control. Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by insulin resistance in accordance with progressive β cell failure and long-term microvascular and macrovascular complications that lead to co-morbidities and mortalities. Sulfonylureas are one of the insulin secretagogues widely used for the management of type 2 diabetes to lower blood glucose levels. The main effect of SUs is thought to be effective when residual pancreatic β-cells are present, as they work by stimulating the release of insulin from the pancreatic beta cells and they are also thought to exert extra-pancreatic effects, such as increasing the insulin-mediated peripheral glucose uptake. Glimepiride works by stimulating the secretion of insulin granules from
Garlic allergenic extract is used in allergenic testing.
Glimepiride {u} (Compound) resembles {v} (Compound) Gliclazide
Glimepiride {u} (Compound) resembles {v} (Compound) Glisoxepide
Glimepiride {u} (Compound) treats {v} (Disease) type 2 diabetes mellitus
Glimepiride {u} (Compound) binds {v} (Gene) KCNJ11
Glimepiride {u} (Compound) is included by {v} (Pharmacologic Class) Sulfonylurea Compounds
Glimepiride {u} (Compound) causes {v} (Side Effect) Inappropriate antidiuretic hormone secretion
Glimepiride {u} may cause a minor interaction that can limit clinical effects when taken with {v} Methylcellulose
Glimepiride {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lipoic acid
Glimepiride {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Chromium picolinate
Glimepiride {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sermorelin
Glimepiride (Compound) resembles Gliclazide (Compound)
Glimepiride (Compound) resembles Glisoxepide (Compound)
Glimepiride (Compound) treats type 2 diabetes mellitus (Disease)
Glimepiride (Compound) binds KCNJ11 (Gene)
Glimepiride (Compound) is included by Sulfonylurea Compounds (Pharmacologic Class)
Glimepiride (Compound) causes Inappropriate antidiuretic hormone secretion (Side Effect)
Glimepiride may cause a minor interaction that can limit clinical effects when taken with Methylcellulose
Glimepiride may cause a minor interaction that can limit clinical effects when taken with Lipoic acid
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Chromium picolinate
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Sermorelin